https://www.selleckchem.com/products/FTY720.html
Perioperative low-dose hANP administration is feasible and safe in patients with curative colorectal cancer. To assess the prophylactic efficacy of postoperative single intravesical instillation with pirarubicin (THP) and mitomycin C (MMC) for low-risk non-muscle-invasive bladder cancer (NMBC). A total of 103 clinically low-risk NMBC patients were preoperatively randomized into either THP (n=49) or MMC (n=54) groups. The primary endpoint was recurrence-free survival. The median follow-up periods of the THP and MMC groups were 955 and 100
Like
Comment
Share
